FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013411189> ?p ?o ?g. }

• W3013411189 abstract "Abstract Background We have previously shown that HCC patients and healthy subjects are equally responsive to a RNAdjuvant ® , a novel TLR-7/8/RIG-I agonist based on noncoding RNA developed by CureVac, by an ex vivo evaluation. However, the immunological effect of adjuvants on immune cells from cancer patients undergoing chemotherapy remains to be demonstrated. Different adjuvants currently used in cancer vaccine clinical trials were evaluated in the present study on immune cells from cancer patients before and after chemotherapy in an ex vivo setting. Methods PBMCs were obtained from 4 healthy volunteers and 23 patients affected by either colon (OMA) or lung cancer (OT). The effect of CpG, Poly I:C, Imiquimod and RNA-based adjuvant (RNAdjuvant ® ) was assessed using a multiparametric approach to analyze network dynamics of early immune responses. Evaluation of CD80, CD86 and HLA-DR expression as well as the downstream effect on CD4 + T cell phenotyping was performed by flow cytometry; cytokine and chemokine production was evaluated by Bio-Plex ProTM. Results Treatment with RNAdjuvant ® induced the strongest response in cancer patients in terms of activation of innate and adoptive immunity. Indeed, CD80, CD86 and HLA-DR expression was found upregulated in circulating dendritic cells, which promoted a CD4 + T cell differentiation towards an effector phenotype. RNAdjuvant ® was the only one to induce most of the cytokines/chemokines tested with a pronounced Th1 cytokine pattern. According to the different parameters evaluated in the study, no clear cut difference in immune response to adjuvants was observed between healthy subjects and cancer patients. Moreover, in the latter group, the chemotherapy treatment did not consistently correlate to a significant altered response in the different parameters. Conclusions The present study is the first analysis of immunological effects induced by adjuvants in cancer patients who undergo chemotherapy, who are enrolled in the currently ongoing cancer vaccine clinical trials. The results show that the RNAdjuvant ® is a potent and Th1 driving adjuvant, compared to those tested in the present study. Most importantly, it is demonstrated that chemotherapy does not significantly impair the immune system, implying that cancer patients are likely to respond to a cancer vaccine even after a chemotherapy treatment." @default.
• W3013411189 created "2020-04-03" @default.
• W3013411189 creator A5015123852 @default.
• W3013411189 creator A5024725865 @default.
• W3013411189 creator A5025181549 @default.
• W3013411189 creator A5027522788 @default.
• W3013411189 creator A5044359811 @default.
• W3013411189 creator A5045703385 @default.
• W3013411189 creator A5051933262 @default.
• W3013411189 creator A5065701928 @default.
• W3013411189 creator A5076878292 @default.
• W3013411189 creator A5083373234 @default.
• W3013411189 creator A5088304855 @default.
• W3013411189 creator A5089373718 @default.
• W3013411189 date "2020-01-23" @default.
• W3013411189 modified "2023-09-26" @default.
• W3013411189 title "Immunological effects of adjuvants in subsets of antigen presenting cells of cancer patients undergoing chemotherapy" @default.
• W3013411189 cites W1542274878 @default.
• W3013411189 cites W1591291198 @default.
• W3013411189 cites W1812103479 @default.
• W3013411189 cites W1917892434 @default.
• W3013411189 cites W1943823376 @default.
• W3013411189 cites W1981480494 @default.
• W3013411189 cites W1984618863 @default.
• W3013411189 cites W2008253296 @default.
• W3013411189 cites W2020376933 @default.
• W3013411189 cites W2033505817 @default.
• W3013411189 cites W2034751554 @default.
• W3013411189 cites W2065855084 @default.
• W3013411189 cites W2078142696 @default.
• W3013411189 cites W2093156470 @default.
• W3013411189 cites W2094158049 @default.
• W3013411189 cites W2110223801 @default.
• W3013411189 cites W2110628542 @default.
• W3013411189 cites W2110632746 @default.
• W3013411189 cites W2120404094 @default.
• W3013411189 cites W2132677838 @default.
• W3013411189 cites W2146352958 @default.
• W3013411189 cites W2151777859 @default.
• W3013411189 cites W2163589263 @default.
• W3013411189 cites W2171156044 @default.
• W3013411189 cites W2179558859 @default.
• W3013411189 cites W2210453860 @default.
• W3013411189 cites W2289160872 @default.
• W3013411189 cites W2308389558 @default.
• W3013411189 cites W2460044542 @default.
• W3013411189 cites W2552598756 @default.
• W3013411189 cites W2581994937 @default.
• W3013411189 cites W2595163384 @default.
• W3013411189 cites W2607106726 @default.
• W3013411189 cites W2626018758 @default.
• W3013411189 cites W2724154348 @default.
• W3013411189 cites W2779802669 @default.
• W3013411189 cites W2796858753 @default.
• W3013411189 cites W2801251447 @default.
• W3013411189 cites W2806769252 @default.
• W3013411189 cites W2809886276 @default.
• W3013411189 cites W2891084688 @default.
• W3013411189 cites W2896033748 @default.
• W3013411189 cites W2945008187 @default.
• W3013411189 cites W4238628024 @default.
• W3013411189 doi "https://doi.org/10.1186/s12967-020-02218-x" @default.
• W3013411189 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6977281" @default.
• W3013411189 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31973714" @default.
• W3013411189 hasPublicationYear "2020" @default.
• W3013411189 type Work @default.
• W3013411189 sameAs 3013411189 @default.
• W3013411189 citedByCount "10" @default.
• W3013411189 countsByYear W30134111892020 @default.
• W3013411189 countsByYear W30134111892021 @default.
• W3013411189 countsByYear W30134111892022 @default.
• W3013411189 countsByYear W30134111892023 @default.
• W3013411189 crossrefType "journal-article" @default.
• W3013411189 hasAuthorship W3013411189A5015123852 @default.
• W3013411189 hasAuthorship W3013411189A5024725865 @default.
• W3013411189 hasAuthorship W3013411189A5025181549 @default.
• W3013411189 hasAuthorship W3013411189A5027522788 @default.
• W3013411189 hasAuthorship W3013411189A5044359811 @default.
• W3013411189 hasAuthorship W3013411189A5045703385 @default.
• W3013411189 hasAuthorship W3013411189A5051933262 @default.
• W3013411189 hasAuthorship W3013411189A5065701928 @default.
• W3013411189 hasAuthorship W3013411189A5076878292 @default.
• W3013411189 hasAuthorship W3013411189A5083373234 @default.
• W3013411189 hasAuthorship W3013411189A5088304855 @default.
• W3013411189 hasAuthorship W3013411189A5089373718 @default.
• W3013411189 hasBestOaLocation W30134111891 @default.
• W3013411189 hasConcept C121608353 @default.
• W3013411189 hasConcept C126322002 @default.
• W3013411189 hasConcept C13373296 @default.
• W3013411189 hasConcept C150903083 @default.
• W3013411189 hasConcept C154317977 @default.
• W3013411189 hasConcept C202751555 @default.
• W3013411189 hasConcept C203014093 @default.
• W3013411189 hasConcept C207001950 @default.
• W3013411189 hasConcept C26291073 @default.
• W3013411189 hasConcept C2776090121 @default.
• W3013411189 hasConcept C2777701055 @default.
• W3013411189 hasConcept C2777863537 @default.
• W3013411189 hasConcept C2778297628 @default.
• W3013411189 hasConcept C2778690821 @default.

• next